AB041. Effectiveness and cost impact evaluation of fluticasone propionate/formoterol compared to fluticasone propionate/salmeterol

Background Treatment of asthmatics with an inhaledcorticosteroid (ICS) and long-acting beta agonist (LABA) is recommended for maintenance treatment according to Step 3 in the GINA guidelines. Fixed-dose combination(FDC) inhalerssimplify the dosing regimen and may improve adherence over their separate components. However, the effectiveness and cost impact of FDC devices containing fluticasone propionate/ formoterol( FP/FOR) compared to fluticasone/ salmeterol( FP/SAL) in asthma patients who initiate or switch to FDC ICS/LABA inhalershave not been studied in real-life patients in the United Kingdom. To determine whether FP/FOR is non-inferior to FP/SAL in patients who initiate or switch to a FDC ICS/LABA therapy with respect to decreasing the occurrence of asthma exacerbationsand overall cost impact.